R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Gene therapyHuidaGene Biotechnology

HuidaGene Secures Patent for Innovative CRISPR-Cas12i System in China

BiotechSHE: 300482

Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership

BiotechHKG: 2607

Shanghai Pharmaceuticals’ SH-INNO Incubator to Drive Biopharmaceutical Innovation and Collaboration

China National Biotec GroupCNBG

CNBG and University of Macau Ink Deal to Establish Joint Biotech Lab

Show More